Alembic Pharma gets USFDA EIR for 2 API facilities in Panelav

Vadodara: Alembic Pharma has announced that the Company has received Establishment Inspection Report (EIR) for the inspection carried out by the US Food and Drug Administration (USFDA) at its API - I & API - II Facility located at Panelav. The EIR follows the inspection conducted from 26th May, 2025 to 31st May, 2025. During the inspection, the facilities initially received four observations. Now EIR has been issued. Read also: Alembic Pharma gets four USFDA observations for Panelav facility Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.